WASHINGTON / RankWire.AI / – Research conducted by the Dana-Farber Cancer Institute and the 23andMe Research Institute reveals that a rare inherited genetic change significantly elevates an individual’s overall chance of developing lung cancer by about 25 times, with non-smokers facing an approximately 60-fold increase, as detailed in the journal Science. The extensive analysis examined anonymized genomic data from more than 3.3 million people. The investigators identified the germline mutation, known as EGFR T790M, as one of the most potent inherited risk factors for lung cancer discovered so far.
This mutation is located within the epidermal growth factor receptor gene, which governs cell growth and division in lung tissue. Although somatic EGFR mutations acquired during life are established contributors to non-small cell lung cancer, the T790M germline variant is inherited from birth and present in every cell. Data from the National Cancer Institute indicates that this mutation occurs in roughly 1 in every 15,850 people in the United States. Lead researcher Dr. Jaclyn LoPiccolo pointed out that carrying this variant increases lung cancer risk by about 62 times for never-smokers, compared to approximately 11 times for those with a history of smoking.
Genetic lineage analysis demonstrated that the EGFR T790M mutation is disproportionately common among populations in Southern Appalachia, particularly in parts of Tennessee and Alabama. Evolutionary geneticists traced the mutation back to British and Irish settlers who migrated to North America during colonial times. The mutation became more prevalent following a genetic bottleneck about 200 years ago. Senior study author Dr. Pasi A. Jänne emphasized that although current lung cancer screening primarily considers tobacco exposure, recognizing significant genetic risk factors could pave the way for targeted screening approaches such as low-dose computed tomography in non-smoking carriers.
Dana-Farber Study Analyzes Genomes of 3.3 Million Individuals
Supported by the National Institutes of Health, the research confirmed that the mutation has a strong specific correlation with lung cancer, showing no notable association with 17 other common cancers evaluated in the dataset. Oncologists highlighted that while tobacco use remains the primary cause of lung cancer overall, the increasing incidence of lung cancer among non-smokers is a growing global health concern. Pharmaceutical companies, such as AstraZeneca, continue to develop targeted therapies like Tagrisso, a tyrosine kinase inhibitor, to treat lung cancers driven by EGFR mutations once tumors progress.
Co-lead researcher Dr. Alexander Gusev observed that this study illustrates how a single inherited point mutation can have an extraordinarily potent impact on disease risk. Medical professionals recommend that individuals with multiple affected family members, unexplained multifocal lung nodules, or ancestral ties to Southern Appalachia seek genetic counseling. The researchers stress that possessing the mutation does not guarantee lung cancer development; environmental factors and additional genetic modifications also influence whether malignant transformation occurs over an individual’s lifetime.
EGFR Gene Impacts Cell Growth Dynamics
The research team intends to expand ongoing observational efforts through the INHERIT Study to investigate other inherited EGFR variants across diverse racial groups. Long-term monitoring aims to identify environmental triggers and secondary genetic changes that determine why some carriers develop tumors while others do not.
Comprehensive details on population genetics, risk assessments, and screening guidelines remain available through peer-reviewed medical repositories and institutional publications. Findings will be presented at upcoming international oncology conferences, guiding future recommendations for screening practices.